Tyrosine Kinase Inhibitor STI571 (Imatinib) Cooperates with Wild-Type p53 on K562 Cell Line to Enhance Its Proapoptotic Effects

Publisher： Karger

E-ISSN： 1421-9662|114|3|150-154

ISSN： 0001-5792

Source： Acta Haematologica, Vol.114, Iss.3, 2005-10, pp. : 150-154

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 1002-1009

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non–small cell lung cancer

By  

CANCER, Vol. 120, Iss. 15, 2014-08 ,pp. : 2299-2307

John Wiley & Sons Inc

Access to resources Recommend Favorite

Expression of Wild-Type p53 and Bcl-2 Family Genes Oscillates with Recurrent Remission and Relapse in an Unusual Case of Low-Grade Lymphoma

By  

Acta Haematologica, Vol. 103, Iss. 4, 2000-09 ,pp. : 177-185

Karger

Access to resources Recommend Favorite

Inhibition of wild‐type p53‐induced phosphatase 1 promotes liver regeneration in mice by direct activation of mammalian target of rapamycin

By  

HEPATOLOGY, Vol. 61, Iss. 6, 2015-06 ,pp. : 2030-2041

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of the MEK inhibitor cobimetinib for wild‐type BRAF Erdheim‐Chester disease

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 1, 2018-01 ,pp. : 150-153

John Wiley & Sons Inc

Access to resources Recommend Favorite